- Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.
- Moderna and Merck developed personalized mRNA cancer vaccine Intismeran following trial success, leading to a surge in Moderna's shares.
Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
5 reports, 2 independent
Updated Sep 22
Gone quiet
- Reports
- 5
- Developments
- 2
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Keep exploring
The entities involved
Related events
- Berkshire Hathaway and Warren Buffett commented on the Moderna and Merck partnership, criticizing market speculation while noting positive news regarding the mRNA vaccine collaboration.
- Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.
- Moderna, Merck, and the National Cancer Institute announced successful trial results for a combined cancer vaccine and immunotherapy program.
- Robert F. Kennedy Jr. collaborated on major cancer vaccine trials while criticizing mRNA technology and its potential funding.
- A market rally was observed in the biotech sector, driven by positive cancer vaccine news, causing Eli Lilly shares to rise.